Stromal expression of ASPN in the TME of HER2/HER3-expressing metastatic prostate cancers is frequently observed in patient samples, supporting the clinical relevance of these findings and highlighting a potential therapeutic vulnerability. Here, ERBB3 is linked to prostate carcinoma.